ECP 2018 Final Programme

Monday, 10 Sept 173 ECP 2018 · Bilbao Breakfast and Luncheon Industry Symposia LS-04 Industry Symposium 13:00 – 14:30 Room E BRAF Mutation Testing in the Evolving Melanoma Treatment Landscape (Novartis) Chair: Nicola Normanno, Italy 001 13:00 – 13:10 Welcome & introduction Nicola Normanno, Italy 002 13:10 – 13:25 The evolving landscape of melanoma treatment Alexander C.J. van Akkooi, The Netherlands 003 13:25 – 13:40 Current testing methods for BRAF mutations in melanoma Nicola Normanno, Italy 004 13:40 – 13:55 Current and future directions in melanoma biomarkers Sandi Deans, United Kingdom 005 13:55 – 14:25 Q&A with panel Nicola Normanno, Italy 006 14:25 – 14:30 Closing remarks Nicola Normanno, Italy e Monday, 10 September 2018 BRM-01 Industry Symposium 07:15 – 08:15 Room B1 Next-generation tomour molecular profiling, practical cases (HTG) Chair: Catherine Wolf, France 001 Molecular Profiling at the Local Level Catherine Wolf, France 002 Breast cancer recurrence risk and subtyping Jose Antonio López Guerrero, Spain 003 Nuclease protection assay is a reliable multiplex approach to detect gene fusions in lung cancer Hans-Ulrich Schildhaus, Germany LS-05 Industry Symposium 13:00 – 14:30 Room A3 Liquid biopsy applications in cancer research using the AVENIO Oncology Assays (Roche) Chair: Mike Hubank, United Kingdom 001 13:00 – 13:20 Circulating tumour DNA as a clinical cancer biomarker: Evaluation of the Roche Avenio approach to plasma-based mutational profiling Mike Hubank, United Kingdom 002 13:20 – 13:40 Practical implementation and validation of ctDNA using targeted NGS: Workflow experience and first results from clinical cohorts Daan van den Broek, The Netherlands 003 13:40 – 14:00 High resolution ctDNA analysis for monitoring response to immune therapy in NSCLC patients Ellen Heitzer, Austria Sunday, 9 Sept

RkJQdWJsaXNoZXIy Mzg2Mjgy